H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Biohaven (BHVN) to $10 from $11 and keeps a Neutral rating on the shares. The firm remains cautious ahead of Biohaven’s opakalim readout in focal-onset seizures expected in the second half of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven price target lowered to $14 from $15 at BofA
- Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity
- Biohaven reports Q4 adjusted EPS (90c), consensus (96c)
- Biohaven initiated with a Buy at Goldman Sachs
- Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s